Technology choice, glycemic control and patient-reported outcome measures in adults with type 1 diabetes: A randomized crossover trial comparing a smart insulin pen with an automated insulin delivery system (EBIACE-1).

Diabetes Res Clin PractAug 18, 2026 (epub)
Clinical ResearchEndocrinology

Teresa Ruiz Gracia, Lía Nattero-Chávez, Alfonso Arranz Martín et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized crossover trial evaluated glycemic outcomes and patient-reported outcomes in 31 adults with type 1 diabetes using a smart insulin pen (SIP) versus an automated insulin delivery (AID) system. AID significantly improved time in range (TIR) at 81% compared to 66% with SIP, and reduced HbA1c by 0.4%.

Key findings

  • AID improved TIR to 81% compared to 66% with SIP, a difference of +15%.
  • AID reduced HbA1c to 6.9% versus 7.3% with SIP, a decrease of -0.4%.
  • 46% of participants achieved near-optimal glycemic control with SIP.
  • Higher baseline diabetes-related life interference correlated with lower likelihood of achieving near-optimal control.

Why it matters

Understanding the comparative effectiveness of insulin delivery technologies is crucial for optimizing glycemic control in type 1 diabetes. This study highlights the potential for personalized technology selection based on individual patient needs and responses.

Source

PubMed · PMID 42612915

Published in Diabetes Res Clin Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.